Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial
Link Medical Journal · 2026
DOI: 10.61919/061x6w21 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Link Medical Journal, 2026. Verfasst von Marriam Abid und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Early-onset type 2 diabetes mellitus is characterized by higher exposure to cardiometabolic risk throughout life and increased risk of cardiovascular morbidity. GLP-1 receptor agonists and SGLT2 inhibitors improve the markers of cardiometabolic risk; however, a comparison between the therapies is poorly represented in the literature regarding younger population.
Objective
Comparative study of the short-term effects of GLP-1 receptor agonist and SGLT2 inhibitor therapy on the markers of cardiometabolic risk in patients with early-onset type 2 diabetes mellitus.
Methods
A randomized parallel group clinical trial was conducted in 84 patients with early-onset type 2 diabetes mellitus. Patients were randomized to receive once weekly GLP-1 receptor agonist therapy or once daily SGLT2 inhibitor therapy for 6 weeks. Main outcomes were changes in systolic blood pressure (SBP), diastolic blood pressure (DBP) and lipid profile. Secondary outcomes were BMI, HbA1c, fasting glucose, and frequency of treatment discontinuation due to adverse events.
Results
79 patients completed follow up and were included into available case analysis. Post-intervention SBP and DBP values were lower in SGLT2 inhibitor group in comparison with GLP-1 receptor agonist group. LDL-C values were lower in GLP-1 receptor agonist group. Mean reduction in SBP value was 8.9 ± 3.1 mmHg in GLP-1RA group vs 10.8 ± 3.5 mmHg in SGLT2 inhibitor group. Mean reduction in LDL-C level was 18.5 ± 6.2 mg/dL in GLP-1RA group and 9.2 ± 5.8 mg/dL in SGLT2 inhibitor group.
Conclusion
Both therapeutic interventions led to short-term improvement of the cardiometabolic risk markers in patients with early-onset type 2 diabetes with different beneficial effects of SGLT2 inhibitors on blood pressure reduction and GLP-1RA on LDL-C level reduction
Zitieren
APA
Abid, M., Akhtar, S. G., Razzaq, T., Ullah, Z., Latif, S. A., Qasim, H. M., & Sadiq, M. A. (2026). Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial. Link Medical Journal. https://doi.org/10.61919/061x6w21
Vancouver
Abid M, Akhtar SG, Razzaq T, Ullah Z, Latif SA, Qasim HM, et al. Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial. Link Medical Journal. 2026. doi:10.61919/061x6w21
BibTeX
@article{Abid2026,
author = {Abid, Marriam and Akhtar, Samia Gull and Razzaq, Tabinda and Ullah, Zia and Latif, Shah Abdul and Qasim, Hafiz Muhammad and Sadiq, Muhammad Abbas},
title = {Differential Cardiometabolic Effects of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Early-Onset Type 2 Diabetes: A Randomized Controlled Trial},
journal = {Link Medical Journal},
year = {2026},
doi = {10.61919/061x6w21}
}
EUVIMED